DEA Denies Registration Over Drug-Related Convictions
Published Date: 7/10/2026
Notice
Summary
Ruth Jones, D.O., tried to get a DEA registration but was denied because she was convicted of serious drug-related crimes and banned from federal health programs. She missed the deadline to ask for a hearing, so the case was closed against her. This means she can’t legally handle controlled substances, affecting her medical practice and career.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Denied Effective Aug 10, 2026
The DEA denied Ruth Jones, D.O.'s pending application for a DEA Certificate of Registration (Control No. W23004273C) and also denied any other pending application of hers for additional registration in Pennsylvania. The Order is effective August 10, 2026.
Existing HHS/OIG Exclusion Confirmed
The record shows the U.S. Department of Health and Human Services, Office of Inspector General mandatorily excluded Ruth Jones from Medicare, Medicaid, and all federal health care programs effective July 20, 2022, for a minimum period of five years. The DEA relied on that exclusion in denying her registration under 21 U.S.C. 824(a)(5).
Missed Hearing Request Causes Default
Because the applicant did not timely file a request for hearing after the DEA's Order to Show Cause, she was deemed in default and the factual allegations in the OSC were admitted. The DEA sought final agency action based on that default, and the Chief ALJ terminated proceedings for untimeliness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-13990, Mariana Moualem, F.N.P.; Decision and Order
Mariana Moualem, a nurse practitioner from California, lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing to fight this, so the DEA moved forward and officially revoked her registration. This means she can’t legally prescribe or handle certain drugs anymore, effective immediately, with no money penalties mentioned.
Next: 2026-13992, Timothy Genetta, D.O.; Decision and Order
Dr. Timothy Genetta from Ohio lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he must stop prescribing or handling these drugs immediately, with no money or timing benefits for him.